Drug intelligence / Profile preview

CPI-11

Development stage: Preclinical
Lead developer: Roswell Park Comprehensive Cancer Center
Modality: Small Molecules

Overview

CPI-11 is a small molecule transcriptional inhibitor of CYP24A1, the primary enzyme responsible for the degradation of 1á,25-dihydroxyvitamin D3 (1,25D3). Identified through a high-throughput screen of the DIVERSet™ library by researchers at the Roswell Park Cancer Institute, CPI-11 was selected for its ability to inhibit 1,25D3-induced CYP24A1 promoter activity. By reducing the expression of CYP24A1, CPI-11 aims to prevent the rapid local inactivation of vitamin D in tumor environments, thereby potentially enhancing the anti-proliferative and pro-apoptotic effects of 1,25D3 in various cancers, including prostate, bladder, and kidney cancer.

Targets

CYP24A1 (Cytochrome P450 family 24 subfamily A member 1)

Beyond the preview

Go deeper on CPI-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPI-11.

Explore the full profile